PhaseBio Pharmaceuticals (NASDAQ:PHAS) announces preliminary data from its Phase 2a clinical trial of PB2452.
The trial includes older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin.
Statistically significant reversal of ticagrelor was achieved within 5 minutes of the PB2452 infusion initiation and sustained for over 20 hours. Platelet function was normalized by 15 minutes following initiation and remained normal for over 20 hours.
PHAS shares are up 12% after hours to $13.71.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.